Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kjersti Flatmark

Showing results (21-30 of 133) with videos related to

Pageof 14
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 17, 2007
Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?Sigurd Folkvord, Kjersti Flatmark, Therese Seierstad, et al.
Human Pathology|March 27, 2010
Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal modelsKjersti Flatmark, Ben Davidson, Alexandr Kristian, et al.
Clinical & Experimental Metastasis|September 22, 2019
Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritoneiOlaf Sørensen, Anders Mikal Andersen, Stein Gunnar Larsen, et al.
Neoplasia (New York, N.Y.)|May 31, 2007
Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude miceTherese Seierstad, Sigurd Folkvord, Kathrine Røe, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 6, 2009
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sitesGunhild M Maelandsmo, Vivi Ann Flørenes, Mai T P Nguyen, et al.
Annals of Surgical Oncology|August 11, 2025
Intraperitoneal Perfusion with Cisplatin or Mitomycin C Improves Survival in Mice Bearing Peritoneal Metastases from Ovarian CancerYvonne Andersson, Emil Løvstakken, Theodor Malmer Herud, et al.
BMC Cancer|July 28, 2016
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screeningErta Kalanxhi, Helga Helseth Hektoen, Sebastian Meltzer, et al.
BMC Cancer|August 21, 2014
B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcomeVibeke A Ingebrigtsen, Kjetil Boye, Jahn M Nesland, et al.
The Journal of Surgical Research|August 9, 2005
Matrix metalloproteinases participate in osteosarcoma invasionKristin Bjørnland, Kjersti Flatmark, Solveig Pettersen, et al.
Cancers|July 2, 2021
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical RationaleYvonne Andersson, Karianne G Fleten, Torveig W Abrahamsen, et al.
Pageof 14

Showing results (21-30 of 133) with videos related to

Sort By:
Pageof 14
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 17, 2007
Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?Sigurd Folkvord, Kjersti Flatmark, Therese Seierstad, et al.
Human Pathology|March 27, 2010
Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal modelsKjersti Flatmark, Ben Davidson, Alexandr Kristian, et al.
Clinical & Experimental Metastasis|September 22, 2019
Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritoneiOlaf Sørensen, Anders Mikal Andersen, Stein Gunnar Larsen, et al.
Neoplasia (New York, N.Y.)|May 31, 2007
Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude miceTherese Seierstad, Sigurd Folkvord, Kathrine Røe, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 6, 2009
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sitesGunhild M Maelandsmo, Vivi Ann Flørenes, Mai T P Nguyen, et al.
Annals of Surgical Oncology|August 11, 2025
Intraperitoneal Perfusion with Cisplatin or Mitomycin C Improves Survival in Mice Bearing Peritoneal Metastases from Ovarian CancerYvonne Andersson, Emil Løvstakken, Theodor Malmer Herud, et al.
BMC Cancer|July 28, 2016
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screeningErta Kalanxhi, Helga Helseth Hektoen, Sebastian Meltzer, et al.
BMC Cancer|August 21, 2014
B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcomeVibeke A Ingebrigtsen, Kjetil Boye, Jahn M Nesland, et al.
The Journal of Surgical Research|August 9, 2005
Matrix metalloproteinases participate in osteosarcoma invasionKristin Bjørnland, Kjersti Flatmark, Solveig Pettersen, et al.
Cancers|July 2, 2021
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical RationaleYvonne Andersson, Karianne G Fleten, Torveig W Abrahamsen, et al.
Pageof 14